Oridonin Relieves Angiotensin II-Induced Cardiac Remodeling Via Inhibiting GSDMD-Mediated Inflammation

Overview

Journal Cardiovasc Ther

Publisher Hindawi

Date 2022 Apr 1

PMID 35360548

Authors

Shuang Lin

Shanshan Dai

Jiahui Lin

Xiaohe Liang

Weiqi Wang

Weijian Huang

Bozhi Ye

Xia Hong

Affiliations

Soon will be listed here.

Abstract

Myocardial remodeling is one of the main lesions in the late stage of chronic heart failure and seriously affects the prognosis of patients. Continuous activation of the renin-angiotensin-aldosterone system (RAAS) contributes to the development of myocardial remodeling greatly, and angiotensin II (Ang II), its main constituent, can directly lead to cardiac remodeling through an inflammatory response and oxidative stress. Since Ang II-induced myocardial remodeling is closely related to inflammation, we tried to explore whether the anti-inflammatory drug oridonin (Ori) can reverse this process and its possible mechanism. Our study investigated that hypertrophy and fibrosis can be induced after being treated with Ang II in cardiomyocytes (H9c2 cells and primary rat cardiomyocytes) and C57BL/6J mice. The anti-inflammatory drug oridonin could effectively attenuate the degree of cardiac remodeling both in vivo and vitro by inhibiting GSDMD, a key protein of intracellular inflammation which can further activate kinds of inflammation factors such as IL-1 and IL-18. We illustrated that oridonin reversed cardiac remodeling by inhibiting the process of inflammatory signaling through GSDMD. After inhibiting the expression of GSDMD in cardiomyocytes by siRNA, it was found that Ang II-induced hypertrophy was attenuated. These results suggest that oridonin is proved to be a potential protective drug against GSDMD-mediated inflammation and myocardial remodeling.

Citing Articles

Role of gasdermin D in inflammatory diseases: from mechanism to therapeutics.

Cheng C, Yi M, Wang L, Huang Y Front Immunol. 2024; 15:1456244.

PMID: 39253076 PMC: 11381298. DOI: 10.3389/fimmu.2024.1456244.

Pharmacological Inhibition of Gasdermin D Suppresses Angiotensin II-Induced Experimental Abdominal Aortic Aneurysms.

Guo J, Shi J, Qin M, Wang Y, Li Z, Shoji T Biomolecules. 2023; 13(6).

PMID: 37371479 PMC: 10295961. DOI: 10.3390/biom13060899.

References

Reudelhuber T, Bernstein K, Delafontaine P . Is angiotensin II a direct mediator of left ventricular hypertrophy? Time for another look. Hypertension. 2007; 49(6):1196-201. PMC: 3227117. DOI: 10.1161/HYPERTENSIONAHA.106.075085. View

Sokolova M, Ranheim T, Louwe M, Halvorsen B, Yndestad A, Aukrust P . NLRP3 Inflammasome: A Novel Player in Metabolically Induced Inflammation-Potential Influence on the Myocardium. J Cardiovasc Pharmacol. 2019; 74(4):276-284. DOI: 10.1097/FJC.0000000000000704. View

Zhang M, Prosser B, Bamboye M, Gondim A, Santos C, Martin D . Contractile Function During Angiotensin-II Activation: Increased Nox2 Activity Modulates Cardiac Calcium Handling via Phospholamban Phosphorylation. J Am Coll Cardiol. 2015; 66(3):261-272. PMC: 4509515. DOI: 10.1016/j.jacc.2015.05.020. View

Wang W, Chen D, Jiang M, Xu B, Li X, Chu Y . Downregulation of gasdermin D promotes gastric cancer proliferation by regulating cell cycle-related proteins. J Dig Dis. 2018; 19(2):74-83. DOI: 10.1111/1751-2980.12576. View

Sadoshima J, Izumo S . Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res. 1993; 73(3):413-23. DOI: 10.1161/01.res.73.3.413. View

Bracey N, Gershkovich B, Chun J, Vilaysane A, Meijndert H, Wright Jr J . Mitochondrial NLRP3 protein induces reactive oxygen species to promote Smad protein signaling and fibrosis independent from the inflammasome. J Biol Chem. 2014; 289(28):19571-84. PMC: 4094069. DOI: 10.1074/jbc.M114.550624. View

Weber K, Brilla C . Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991; 83(6):1849-65. DOI: 10.1161/01.cir.83.6.1849. View

Wakui H, Tamura K, Tanaka Y, Matsuda M, Bai Y, Dejima T . Cardiac-specific activation of angiotensin II type 1 receptor-associated protein completely suppresses cardiac hypertrophy in chronic angiotensin II-infused mice. Hypertension. 2010; 55(5):1157-64. DOI: 10.1161/HYPERTENSIONAHA.109.147207. View

Tao J, Ma Y, Li X, Chen B, Yang Y, Ma X . [An improved protocol for primary culture of cardiomyocyte from neonatal rat]. Zhonghua Xin Xue Guan Bing Za Zhi. 2014; 42(1):53-6. View

10.

Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H . Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015; 526(7575):660-5. DOI: 10.1038/nature15514. View

11.

Parameswaran S, Kumar S, Verma R, Sharma R . Cardiomyocyte culture - an update on the in vitro cardiovascular model and future challenges. Can J Physiol Pharmacol. 2013; 91(12):985-98. DOI: 10.1139/cjpp-2013-0161. View

12.

Wang Y, Gao W, Shi X, Ding J, Liu W, He H . Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017; 547(7661):99-103. DOI: 10.1038/nature22393. View

13.

Wang S, Zhang Y, Saas P, Wang H, Xu Y, Chen K . Oridonin's therapeutic effect: suppressing Th1/Th17 simultaneously in a mouse model of Crohn's disease. J Gastroenterol Hepatol. 2014; 30(3):504-12. DOI: 10.1111/jgh.12710. View

14.

Wrigley B, Lip G, Shantsila E . The role of monocytes and inflammation in the pathophysiology of heart failure. Eur J Heart Fail. 2011; 13(11):1161-71. DOI: 10.1093/eurjhf/hfr122. View

15.

Kurdi M, Booz G . New take on the role of angiotensin II in cardiac hypertrophy and fibrosis. Hypertension. 2011; 57(6):1034-8. PMC: 3098302. DOI: 10.1161/HYPERTENSIONAHA.111.172700. View

16.

Jiang D, Zhang X, Gao L, Zong J, Zhou H, Liu Y . Signal regulatory protein-α protects against cardiac hypertrophy via the disruption of toll-like receptor 4 signaling. Hypertension. 2013; 63(1):96-104. PMC: 4422401. DOI: 10.1161/HYPERTENSIONAHA.113.01506. View

17.

Yang H, Lv H, Li H, Ci X, Peng L . Oridonin protects LPS-induced acute lung injury by modulating Nrf2-mediated oxidative stress and Nrf2-independent NLRP3 and NF-κB pathways. Cell Commun Signal. 2019; 17(1):62. PMC: 6558832. DOI: 10.1186/s12964-019-0366-y. View

18.

Sokolova M, Sjaastad I, Louwe M, Alfsnes K, Aronsen J, Zhang L . NLRP3 Inflammasome Promotes Myocardial Remodeling During Diet-Induced Obesity. Front Immunol. 2019; 10:1621. PMC: 6648799. DOI: 10.3389/fimmu.2019.01621. View

19.

Zhao Q, Viswanadhapalli S, Williams P, Shi Q, Tan C, Yi X . NADPH oxidase 4 induces cardiac fibrosis and hypertrophy through activating Akt/mTOR and NFκB signaling pathways. Circulation. 2015; 131(7):643-55. PMC: 4568756. DOI: 10.1161/CIRCULATIONAHA.114.011079. View

20.

Meng X, Yu X, Liu C, Wang Y, Song F, Huan C . Effect of ingredients from Chinese herbs on enterovirus D68 production. Phytother Res. 2018; 33(1):174-186. DOI: 10.1002/ptr.6214. View